Institut Claudius Regaud
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
May 2035
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jul 28, 2027The maintenance fee for Anti-Rho Gtpase Conformational Single Domain Antibodies and Uses Thereof (US 10,544,210) comes due Jul 28, 2027. Unpaid by Jan 28, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
- Sep 22 US 12,740,979 Methods for the Treatment of Cancers That Have Acquired Resistance to Kinase Inhibitors
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 4 of 4
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,144,772 | New Method for Treating Melanoma In force · High confidence | In force | High confidence | |
| US 10,544,210 | Anti-Rho Gtpase Conformational Single Domain Antibodies and Uses Thereof In force · High confidence | In force | High confidence | |
| US 11,186,634 | Antibodies Targeting Tumor Associated Macrophages and Uses Thereof In force · High confidence | In force | High confidence | |
| US 12,740,979 | Methods for the Treatment of Cancers That Have Acquired Resistance to Kinase Inhibitors In force · High confidence | In force | High confidence |
Also on record, not counted in the 4: 2 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 1 abandoned · 2 no status recorded
Showing 1 to 5 of 5, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.
| Application | Title | Filed | Status |
|---|---|---|---|
| 18/856,328 | Combination of Ras Inhibitors and Farnesyltransferase Inhibitors for the Treatment of Cancers | Apr 27, 2023 | Pending |
| 17/700,624 | Anti-Rho Gtpase Conformational Single Domain Antibodies and Uses Thereof | Mar 22, 2022 | Abandoned |
| 18/257,383 | Diagnostic Method for Cancer Evolution Prediction, and Uses Thereof | Dec 13, 2021 | Pending |
| 17/593,474 | Mar 19, 2020 | No status recorded | |
| 10/548,567 | Mar 12, 2004 | No status recorded |